Related Experiment Video

Updated: Jun 15, 2025

Identification of Circular RNAs using RNA Sequencing
08:25

Identification of Circular RNAs using RNA Sequencing

Published on: November 14, 2019

12.2K

Circular RNAs in tumor immunity and immunotherapy

Wenjie Zhang1,2, Chen Xu1, Zhipeng Yang1,2

  • 1Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China.

Molecular Cancer
|August 21, 2024
PubMed

Insights

Circular RNAs (circRNAs) are key regulators in cancer development and immunity. This review explores how circRNAs influence antitumor immunity and enhance cancer immunotherapy effectiveness, offering new therapeutic targets.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Circular RNAs (circRNAs) are noncoding RNAs with stable, looped structures.
  • circRNAs play roles in gene regulation, acting as miRNA sponges and interacting with proteins.
  • They are implicated in the development of various malignant tumors.

Purpose of the Study:

  • To review current research on circRNAs in antitumor immune regulation.
  • To explore the potential of circRNAs in enhancing cancer immunotherapy efficacy.
  • To identify novel targets for cancer immunotherapy.

Main Methods:

  • Literature review of studies on circRNAs and tumor immunity.
  • Analysis of mechanisms by which circRNAs regulate the tumor immune microenvironment.
  • Evaluation of circRNAs' role in modulating antitumor immune responses.

Main Results:

  • circRNAs are involved in regulating the tumor immune microenvironment and antitumor immunity.
  • circRNAs can potentially increase sensitivity to immunotherapy.
  • Few studies have comprehensively investigated the link between circRNAs and tumor immunity.

Conclusions:

  • circRNAs represent promising targets for improving cancer immunotherapy outcomes.
  • Further research is needed to fully elucidate the role of circRNAs in tumor immunity.
  • Harnessing circRNAs may expand the patient population benefiting from immunotherapy.
Keywords:
Cancer immunotherapyImmunityTumorcircRNAs

More Related Videos

In Silico Identification and Characterization of circRNAs During Host-Pathogen Interactions10:27

In Silico Identification and Characterization of circRNAs During Host-Pathogen Interactions

Published on: October 21, 2022

1.5K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

306

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K